Welcome!

News Feed Item

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256136/Lumbar-Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Lumbar Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lumbar Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lumbar Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lumbar Spinal Stenosis 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Lumbar Spinal Stenosis 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lumbar Spinal Stenosis Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28

Clinical Trial Overview of Top Companies 28
Sucampo Pharmaceuticals, Inc. 28
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 28
United Therapeutics Corporation 29
Clinical Trial Overview of United Therapeutics Corporation 29
Mesoblast Limited 30
Clinical Trial Overview of Mesoblast Limited 30
KT&G Corporation 31
Clinical Trial Overview of KT&G Corporation 31
Kaken Pharmaceutical Co., Ltd. 32
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 32
Clinical Trial Overview of Top Institutes / Government 33
Keio University 33
Clinical Trial Overview of Keio University 33
Hamamatsu University School of Medicine 34
Clinical Trial Overview of Hamamatsu University School of Medicine 34
National University Of Health Sciences 35
Clinical Trial Overview of National University Of Health Sciences 35

University of Manitoba 36
Clinical Trial Overview of University of Manitoba 36
Asan Medical Center 37
Clinical Trial Overview of Asan Medical Center 37
Kobe University 38
Clinical Trial Overview of Kobe University 38
Yonsei University 39
Clinical Trial Overview of Yonsei University 39
Ohio State University 40
Clinical Trial Overview of Ohio State University 40
Leiden University Medical Center 41
Clinical Trial Overview of Leiden University Medical Center 41
Emory University 42
Clinical Trial Overview of Emory University 42
Five Key Clinical Profiles 43
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 67

List of Tables

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Lumbar Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lumbar Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 18

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Lumbar Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 22
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lumbar Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 28
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 29

Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 30
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 31
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 32
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 33
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 34
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National University Of Health Sciences, 2014* 35
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Manitoba, 2014* 36
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 37
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kobe University, 2014* 38
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 39
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University, 2014* 40
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 41
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 42

List of Figures

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Lumbar Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lumbar Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lumbar Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 66

To order this report: Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256136/Lumbar-Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 21st Int\ernational Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their ...
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists looked at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deliver...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), provided an overview of various initiatives to certify the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldwide re...
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...